Literature DB >> 9518284

Hepatic dysfunction associated with troglitazone.

P B Watkins, R W Whitcomb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9518284     DOI： 10.1056/NEJM199803263381314

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  68 in total

1.  Severe but reversible hepatitis induced by troglitazone.

Authors:  T Schiano; K Dolehide; J Hart; A L Baker
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

Review 2.  The glitazones: proceed with caution.

Authors:  D Krische
Journal:  West J Med       Date:  2000-07

3.  Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.

Authors:  B Zhang; M Shiomi; H Tanaka; J Mei; P Fan; Y Tsujita; H Horikoshi; K Saku
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

Review 4.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

Review 5.  [The COMBO project. Criteria and guidelines for combined therapy of type 2 diabetes. Consensus document (and II)].

Authors:  A Goday Arno; A Goday Arno; F Alvarez Guisasola; J Díez Espino; I Fernández Fernández; D Tórtola Graner; D Acosta Delgado; M Aguilar Diosdado; J Herrera Pombo; L Felipe Pallardo
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

6.  Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

Authors:  Susumu Itoh; Azuma Kanazuka; Takahide Akimoto
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

7.  Acute troglitazone action in isolated perfused rat liver.

Authors:  K Preininger; H Stingl; R Englisch; C Fürnsinn; J Graf; W Waldhäusl; M Roden
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 8.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

9.  Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

Authors:  Izna Ali; Seher Khalid; Bruno Stieger; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2019-01-25       Impact factor: 4.939

Review 10.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.